Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BioNTech SE - American Depositary Shares (NQ:BNTX)

93.92 +0.87 (+0.93%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 545,565
Open 93.29
Bid (Size) 92.00 (100)
Ask (Size) 95.00 (100)
Prev. Close 93.05
Today's Range 92.56 - 94.00
52wk Range 79.52 - 124.00
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
2 Biotech Stocks Worth Buying Before Their Potential Buyouts ↗
It has been a banner year for biotech buyouts, and these are two of the prime targets. 
Via The Motley Fool
News headline image
Global Data for BioNTech and Bristol Myers Squibb’s PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial
From BioNTech SE
Via GlobeNewswire

Performance

YTD
-2.9%
-2.9%
1 Month
+2.4%
+2.4%
3 Month
+5.7%
+5.7%
6 Month
-1.4%
-1.4%
1 Year
-11.8%
-11.8%

More News

Read More
News headline image
BioNTech to Showcase Progress Across Late-Stage Oncology Pipeline at the 2026 ASCO Annual Meeting
From BioNTech SE
Via GlobeNewswire
BioNTech Q1 2026 Revenue Miss Overshadows Pipeline Progress as NASDAQ:BNTX Slides ↗
Via Chartmill
BioNTech SE (NASDAQ:BNTX) Stock Plummets 17% on Q4 Loss and Co-Founders' Planned Exit ↗
Via Chartmill
News headline image
BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2026
From BioNTech SE
Via GlobeNewswire
News headline image
BioNTech Maps Oncology Push, $1B Buyback and Manufacturing Cuts at AGM ↗
Via MarketBeat
News headline image
3 Reasons Not to Buy Into the Hantavirus-Related Biotech Rally ↗
Via The Motley Fool
News headline image
Is Bristol Myers Squibb Stock Overvalued at Nearly $60? A Reality Check for Value Investors. ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
BioNTech Announces New ADS Repurchase Program
From BioNTech SE
Via GlobeNewswire
News headline image
BioNTech Announces First Quarter 2026 Financial Results and Corporate Update
From BioNTech SE
Via GlobeNewswire
News headline image
BioNTech to Report First Quarter 2026 Financial Results and Corporate Update on May 5, 2026
From BioNTech SE
Via GlobeNewswire
News headline image
2 Healthcare Stocks to Buy and 1 to Approach With Caution ↗
Via The Motley Fool
News headline image
BioNTech and DualityBio’s Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer
From BioNTech SE
Via GlobeNewswire
News headline image
Moderna 2.0: The mRNA Pioneer’s Pivot to Oncology and the Path to 2028 Profitability
Via Finterra
Topics Initial Public Offering
News headline image
BioNTech Clinical Data at ELCC 2026 Highlight Potential of Differentiated Late-Stage Portfolio in Lung Cancer
From BioNTech SE
Via GlobeNewswire
News headline image
The mRNA Renaissance: Moderna’s 83% Surge Leads the 2026 Healthcare Recovery
Via MarketMinute
Topics Artificial Intelligence Initial Public Offering Stocks
News headline image
Why BioNTech Stock Is Getting Crushed Today ↗
Via The Motley Fool
Gapping stocks in Tuesday's session ↗
Via Chartmill
News headline image
BioNTech Navigates Post-Pandemic Deficit: A €17 Billion Bet on the Oncology Frontier
Via MarketMinute
Stay updated with the stocks that are on the move in today's pre-market session. ↗
Via Chartmill
News headline image
Why Did BNTX Stock Tumble 17% Pre-Market Today? ↗
Via Stocktwits
News headline image
BioNTech Announces Fourth Quarter and Full Year 2025 Financial Results and Corporate Update
From BioNTech SE
Via GlobeNewswire
News headline image
BioNTech and Co-Founders Announce Plan to Pursue Next-Generation mRNA Innovations in Co-Founders-Led New Company as BioNTech Advances Toward Becoming a Multi-Product Company by 2030
From BioNTech SE
Via GlobeNewswire
News headline image
The Moderna Pivot: Analyzing the 14% Surge and the Future of mRNA Oncology
Via Finterra
Topics Initial Public Offering Intellectual Property

Frequently Asked Questions

Is BioNTech SE - American Depositary Shares publicly traded?
Yes, BioNTech SE - American Depositary Shares is publicly traded.
What exchange does BioNTech SE - American Depositary Shares trade on?
BioNTech SE - American Depositary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for BioNTech SE - American Depositary Shares?
The ticker symbol for BioNTech SE - American Depositary Shares is BNTX on the Nasdaq Stock Market
What is the current price of BioNTech SE - American Depositary Shares?
The current price of BioNTech SE - American Depositary Shares is 93.92
When was BioNTech SE - American Depositary Shares last traded?
The last trade of BioNTech SE - American Depositary Shares was at 07/01/26 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.